Sunday, 7 December 2014
Exhibition Hall-Poster Area (Sul America)
Solange Oliveira Rodrigues Valle, PhD
,
Clínica Médica - Imunologia Clínica, Hospital Universitário Clementino Fraga Filho Hucff-Ufrj, Rio de Janeiro, Brazil
Maria Luiza Oliva Alonso, MD
,
Clínica Médica - Imunologia Clínica, Hospital Universitário Clementino Fraga Filho Hucff-Ufrj, Rio de Janeiro, Brazil
Sérgio Duarte Dortas Junior, Msc
,
Clínica Médica, WAO Junior Member, Rio de Janeiro, Brazil
Soloni Afra Pires Levy, MD
,
Alergia e Imunologia Clínica, Hospital São Zacharias, Rio de Janeiro, Brazil
Ana Luiza Ribeiro Bard De Carvalho, MD
,
Clínica Médica - Imunologia Clínica, Hospital Universitário Clementino Fraga Filho Hucff-Ufrj, Rio de Janeiro, Brazil
Ana Paula Ferracciú Coutinho Millet, MD
,
Clínica Médica - Imunologia Clínica, Hospital Universitário Clementino Fraga Filho Hucff-Ufrj, Rio de Janeiro, Brazil
Alfeu Tavares França, PhD
,
Clínica Médica - Imunologia Clínica, Hospital Universitário Clementino Fraga Filho Hucff-Ufrj, Rio de Janeiro, Brazil
Background: HAE is an inherited disease characterized by sudden, recurrent episodes of edema involving the skin, gastrointestinal, respiratory tract and other organs. Pregnancy can mitigate, aggravate or have no effect on HAE C1-INH edematous attacks. Short term prophylaxis is recommended before labor and delivery when HAE C1-INH symptoms have recurred frequently during the third trimester of pregnancy. The administration of pdhC1-INH in HAE is recommended as the first line therapy in pregnancy. It is effective and safe. However, pdhC1-INH is not available in many countries, such as in Brazil. In these cases fresh frozen plasma might serve as an alternative for STP (evidence level III). We describe our experience with pdh C1-INH in two pregnant patients with HAE followed up in a Reference Center in Rio de Janeiro, who received the medicine by means of Justice.
Methods: CASE 1- DFT, a 29-year-old pregnant woman, with HAE Type I (C4 = 5,0 mg/dL e C1-INH = 9,0 mg/dL) and recurrent edema of hands, feets, lips, larynge and abdominal pain. She received 1000 units of pdh C1-INH, intravenously (IV), on the day of delivery. CASE 2 - RSS, a 30 year-old pregnant woman, with HAE Type I (C4 = 5,0 mg/dL e C1-INH = 5,0 mg/dL) and episodes of swelling in the hands, feet and abdominal pain. She also received 1000 units of pdh C1-INH, IV, on the day of delivery.
Results: Both of them had uncomplicated labor under pdh C1-INH prophylaxis. Healthy infants were born.
Conclusions: Our patients could experience uncomplicated labors while being administered prophylactic pdhC1-INH, despite having some attacks of HAE during pregnancy. Short-term prophylaxis is important in individuals with known HAE who are undergoing procedures which can potentially precipitate an attack, as labor. pdhC1-INH concentrate should be always available to be used, if necessary.
